Cancer Endocrinology Group

The Cancer Endocrinology Group pursues collaborative, multi-disciplinary research projects aimed at delineating the impact of altered metabolic conditions on cancer, to determine ways in which risk and progression can be ameliorated and treatment optimised.

We have a particular interest in insulin-like growth factors that are complex fundamental, nutritionally dependent regulators of growth and metabolism and, together with insulin, have been increasingly associated with cancers linked to a Western diet and lifestyle.

The team performs mechanistic studies using cell lines to understand the molecular processes underpinning a range of phenotypes important for tumour development, including proliferation, survival, migration, and invasion. We also play an integral role in clinical studies, through analysis of human samples, including tissue and blood.

Through understanding how cancers respond to different exposures, our work may identify ways of intervening to prevent the cancer developing and for those with cancer, better and more effective ways of treating patients.

[a] Represents immunofluorescent staining of E-cadherin in colon cancer cells, [b] immunohistochemical staining of pmTOR in prostate cancer tissue, [c] prostate cancer cells growing in 3D

Head of Group

Dr Claire Perks, PhD
Associate Professor in Tumour Cell Biology
Head of Section: Metabolism, Clinical Neuroscience & Respiratory
Tel: 0117 41 47897


Cancer Endocrinology Group
Learning and Research Building
Second Floor
Southmead Hospital
Bristol BS10 5NB
United Kingdom
Ashley Gwinn Executive Administrator
Edit this page